LIVISTO listed on Deadlock ransomware leak site

• Ransomware group: Deadlock
• Country: Poland
• Sector: Technology
• Announcement date: July 10, 2026

LIVISTO listed on Deadlock ransomware leak site

The Deadlock ransomware group has published an announcement on its leak site listing the Polish organization LIVISTO as a victim. According to the claims made by the threat actor group, they have successfully gained access to the organization's data. This announcement, which appeared on the group's platform on July 10, 2026, marks a potential security incident for the pharmaceutical company.

Details of the alleged attack

The Deadlock group officially announced the targeting of LIVISTO on July 10, 2026. While the group claims to have breached the organization's systems, specific details regarding the methods used to gain entry remain unavailable. Publicly available information concerning the Deadlock group is currently limited, making it difficult to determine their specific operational patterns or motivations at this time.

In many ransomware scenarios, threat actors employ a strategy known as double extortion. In such cases, attackers do not only encrypt an organization's files to disrupt operations but also exfiltrate sensitive data to use as leverage. By threatening to leak this information on a public site, the attackers aim to pressure the victim into paying a ransom to prevent the disclosure of proprietary or sensitive information. This tactic increases the pressure on the victim, as the breach moves from a purely operational issue to a significant reputational and regulatory risk.

Information regarding the leaked data

At this stage, there is no information regarding the specific content of the leaked data. The screenshot provided by the group does not contain any data samples and only displays an error message. Consequently, the listing names no data types.

About LIVISTO

LIVISTO is an international pharmaceutical company specializing in veterinary health. The organization focuses on developing and manufacturing a wide range of animal health products. Their product portfolio is designed to serve both veterinarians and pet owners globally.

Potential impact and industry considerations

Given the organization's operations in the veterinary pharmaceutical sector, a potential data breach could pose risks to trade secrets or intellectual property rights. The sensitive nature of pharmaceutical research and manufacturing processes means that any loss of data could impact the organization's operational processes and create secondary risks for third parties involved in their supply chain.

Furthermore, as a company based in Poland, LIVISTO may be subject to data protection obligations and potential administrative sanctions under the General Data Protection Regulation (GDPR). Regulatory frameworks like the GDPR impose strict requirements on how organizations handle and protect personal data, and failure to secure such data can lead to significant legal and financial consequences.

To mitigate such risks, organizations in the pharmaceutical and technology sectors often implement various defensive measures. These include robust encryption for data at rest and in transit, multi-factor authentication (MFA) to secure access to sensitive systems, and continuous monitoring of network traffic to detect unauthorized access. Regular security audits and employee training programs are also essential components of a comprehensive cybersecurity posture designed to defend against evolving ransomware threats.

Because there is insufficient data regarding the group's methods and motivations, the scope and impact of the attack remain uncertain. The situation remains developing as more information becomes available regarding the breach and the specific data involved.